Literature DB >> 30527603

Randomised controlled trial begins for Ebola therapeutics.

Esther Nakkazi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30527603     DOI: 10.1016/S0140-6736(18)33011-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Ebola Virus in the Democratic Republic of the Congo: Advances and Remaining Obstacles in Epidemic Control, Clinical Care, and Biomedical Research.

Authors:  Julie Erb-Alvarez; Aaron M Wendelboe; Daniel S Chertow
Journal:  Chest       Date:  2019-09-10       Impact factor: 9.410

2.  Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses.

Authors:  Tianguang Huang; Lin Sun; Dongwei Kang; Vasanthanathan Poongavanam; Xinyong Liu; Peng Zhan; Luis Menéndez-Arias
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.

Authors:  Tomasz J Guzik; Saidi A Mohiddin; Anthony Dimarco; Vimal Patel; Kostas Savvatis; Federica M Marelli-Berg; Meena S Madhur; Maciej Tomaszewski; Pasquale Maffia; Fulvio D'Acquisto; Stuart A Nicklin; Ali J Marian; Ryszard Nosalski; Eleanor C Murray; Bartlomiej Guzik; Colin Berry; Rhian M Touyz; Reinhold Kreutz; Dao Wen Wang; David Bhella; Orlando Sagliocco; Filippo Crea; Emma C Thomson; Iain B McInnes
Journal:  Cardiovasc Res       Date:  2020-08-01       Impact factor: 10.787

Review 4.  Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment.

Authors:  Saptarshi Chatterjee
Journal:  Drug Res (Stuttg)       Date:  2020-10-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.